SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-052056
Filing Date
2024-05-02
Accepted
2024-05-02 16:03:50
Documents
69
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aldx-20240331.htm   iXBRL 10-Q 1609565
2 EX-31.1 aldx-ex31_1.htm EX-31.1 15497
3 EX-31.2 aldx-ex31_2.htm EX-31.2 15785
4 EX-32.1 aldx-ex32_1.htm EX-32.1 11602
5 GRAPHIC img130884783_0.jpg GRAPHIC 77075
  Complete submission text file 0000950170-24-052056.txt   6433735

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aldx-20240331.xsd EX-101.SCH 937511
72 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20240331_htm.xml XML 920919
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 24908053
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)